Brief Summary
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia.
Brief Title
1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Detailed Description
Single-center, open-label, baseline-controlled, pilot study evaluating the use of a Nonablative 1470 nm laser for the treatment of androgenetic alopecia and scarring alopecia. The study may enroll up to 10 participants looking for improvement in their hair loss. All participants will have biopsy-proven alopecia before enrollment. There will be two treatment arms with 5 participants in the androgenetic alopecia arm and 5 participants in the scarring alopecia arm. Multiple treatment areas of the scalp may be performed. Each subject will receive up to three treatments. Follow-up visits are planned for months 6, 9, 12, and 15. Standardized photography, hair density measurement of the treated scalp areas will be recorded Pre and Post Treatment at each visit. Measurement outcomes will be compared to baseline. During the initial visit, subjects who meet the study's eligibility criteria will receive the first treatment after signing informed consent form.
For this study, the investigators will use non-ablative HALO laser (1470nm) (Sciton). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The laser creates controlled zones of coagulation within the dermis. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment procedure will consist of topical anesthetic then cleaning of the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide. Post-treatment care will follow standard of care, including the application of topical betamethasone dipropionate cream 0.05% to the treated area. The U.S. Food and Drug Administration (FDA) has cleared the 1470 nm laser for dermatologic purposes. This study will use the laser off-label for the treatment of alopecia. This laser has been approved for the treatment of skin, however, it has not been tested for the treatment of androgenetic alopecia or scarring alopecia, thus this is a novel study to investigate its effectiveness
The follow up phase will consist of clinical assessments including before and after photographs graded by blinded observers and hair density evaluation using Canfield HairMetrix ® device. Subjects are instructed to inform clinical staff after the treatment if they experience any adverse events and will complete patient questionnaires, pain score, and self-assessment of hair growth.
For this study, the investigators will use non-ablative HALO laser (1470nm) (Sciton). The non-ablative fractionated treatments with minimal downtime provide synergistic benefit of minimizing tissue damage while improving treatment tolerance and efficiency. The laser works by creating micro-channels in the dermis of the pilosebaceous unit, while leaving bridges of untouched tissue for improved permeability, faster healing, and enhanced delivery of topical treatments. The laser creates controlled zones of coagulation within the dermis. The parameters of the laser will be set according to optimal operation protocol and in accordance with guidelines set forth by Sciton. Each laser treatment will take approximately 10 to 15 minutes per subject. Pretreatment procedure will consist of topical anesthetic then cleaning of the affected area of the scalp with antiseptic, either 70% ethanol or 3% hydrogen peroxide. Post-treatment care will follow standard of care, including the application of topical betamethasone dipropionate cream 0.05% to the treated area. The U.S. Food and Drug Administration (FDA) has cleared the 1470 nm laser for dermatologic purposes. This study will use the laser off-label for the treatment of alopecia. This laser has been approved for the treatment of skin, however, it has not been tested for the treatment of androgenetic alopecia or scarring alopecia, thus this is a novel study to investigate its effectiveness
The follow up phase will consist of clinical assessments including before and after photographs graded by blinded observers and hair density evaluation using Canfield HairMetrix ® device. Subjects are instructed to inform clinical staff after the treatment if they experience any adverse events and will complete patient questionnaires, pain score, and self-assessment of hair growth.
Categories
Central Contacts
Central Contact Role
Contact
Central Contact Phone
618-704-8716
Central Contact Email
ajallorina@montefiore.org
Completion Date
Completion Date Type
Estimated
Conditions
SCARRING ALOPECIA
ANDROGENETIC ALOPECIA
Eligibility Criteria
Inclusion Criteria:
* Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss
* Subject must voluntarily sign and date an IRB approved informed consent form
* Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months
* Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months
* Able to read, understand and voluntarily provide written informed consent
* Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study
* Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements
* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period
Exclusion Criteria:
* Subject does not have the capacity to consent to the study
* Subject has other types of alopecia of the scalp like alopecia areata
* History of intralesional steroid injections to the scalp in the last 12 months
* Pregnant women
* Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject
* Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months
* Allergy or history of prior reaction to lidocaine
* History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months
* History or current use of the following prescription medications:
i. Immunosuppressive medications/biologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months
* Smoking or vaping in the past 12 months
* History of uncontrolled hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders
* History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism
* Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss
* Subject must voluntarily sign and date an IRB approved informed consent form
* Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months
* Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months
* Able to read, understand and voluntarily provide written informed consent
* Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study
* Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements
* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period
Exclusion Criteria:
* Subject does not have the capacity to consent to the study
* Subject has other types of alopecia of the scalp like alopecia areata
* History of intralesional steroid injections to the scalp in the last 12 months
* Pregnant women
* Any medical condition that in the consideration of the investigator, would present an increased risk of a photosensitivity reaction to the subject
* Any previous surgical procedure in the treatment area in the past 12 months, or major surgery in the last 6 months
* Allergy or history of prior reaction to lidocaine
* History of immunosuppression/immune deficiency disorders (including AIDS and HIV infection), and/or any history of systemic chemotherapy for prior 12 months
* History or current use of the following prescription medications:
i. Immunosuppressive medications/biologics, 6 months prior to and during the study ii. Accutane or other systemic retinoids within the past twelve months
* Smoking or vaping in the past 12 months
* History of uncontrolled hyperlipidemia, diabetes mellitus, hepatitis, or bleeding disorders
* History of major depressive disorders or endocrine disorders including but not limited to; hypothyroidism, Hashimoto's thyroiditis, or hyperthyroidism
Inclusion Criteria
Inclusion Criteria:
* Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss
* Subject must voluntarily sign and date an IRB approved informed consent form
* Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months
* Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months
* Able to read, understand and voluntarily provide written informed consent
* Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study
* Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements
* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period
* Healthy males and females, ≥ 18 years of age at time of informed consent, seeking treatment for hair loss
* Subject must voluntarily sign and date an IRB approved informed consent form
* Subjects with diagnosis of biopsy proven androgenetic alopecia or scarring alopecia with hair loss recorded over the past 6 months
* Subjects must have a stable hair loss treatment regimen with a plateau in results for at least 3 months
* Able to read, understand and voluntarily provide written informed consent
* Subject is determined to be healthy, non-smoker who agrees not to make any changes to their daily hair treatment regimen during the study
* Subjects able and willing to comply with the treatment protocol and follow-up schedule and requirements
* Understands and accepts the obligation not to undergo any other procedures in the areas to be treated through the follow-up period
Gender
All
Gender Based
false
Keywords
alopecia
laser
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Maximum Age
99 Years
Minimum Age
18 Years
NCT Id
NCT05460611
Org Class
Other
Org Full Name
Montefiore Medical Center
Org Study Id
2022-14192
Overall Status
Recruiting
Phases
Not Applicable
Primary Completion Date
Primary Completion Date Type
Estimated
Official Title
A Pilot Study Evaluating the Safety and Efficacy of a 1470nm Laser for the Treatment of Androgenetic Alopecia and Scarring Alopecia
Primary Outcomes
Outcome Description
Live and Photographic assessment of hair loss will be assessed using the 7-point Clinician rated Global Aesthetic Improvement Scale (CGAIS). The GAIS is a standardized tool used in dermatology and aesthetic medicine to evaluate treatment success for hair loss (such as androgenetic and scarring alopecia). The 7-point GAIS is scored using a scale ranging from -3 (Greatly decreased - hair growth and density) to 3 (Greatly increased - hair growth and density). A score of zero represents no change.
Outcome Measure
Live and Photographic assessment of hair loss
Outcome Time Frame
Month 1 (baseline), Month 2, Month 3, Month 6, Month 9, Month 12, Month 15
Outcome Description
Hair density will be assessed using the Canfield HairMetrix imaging device. The average number of hairs per follicular unit will be summarized by arm using descriptive statistics.
Outcome Measure
Hair Density
Outcome Time Frame
Month 1 (baseline), and during the four follow-up periods at Month 6, Month 9, Month 12, and Month 15 (i.e., up to 14 months after initial treatment)
Outcome Description
Hair counts will also be assessed using the Canfield HairMetrix imaging device. Hair counts/cm\^2 will be summarized by study arm using descriptive statistics.
Outcome Measure
Hair Counts
Outcome Time Frame
Month 1 (baseline), and during the four follow-up periods at Month 6, Month 9, Month 12, and Month 15 (i.e., up to 14 months after initial treatment)
Secondary Outcomes
Outcome Description
Overall subject satisfaction will be assessed using a Patient Satisfaction Questionnaire (PSQ). Participants will be asked to complete the assessment while referring to their image in the mirror and current post-treatment photos compared to baseline photos. Specifically, participants will be asked to "Please choose the option that better represents the change in how your hair looks OVERALL in the area treated?" using a scale ranging from -3 (Greatly decreased) to 3 (Greatly increased). A score of zero represents no change. Scores will be summarized by study arm using descriptive statistics.
Outcome Time Frame
Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, and Month 15
Outcome Measure
Subject Satisfaction - Overall
Outcome Description
Subject satisfaction with hair thickness will be assessed using a Patient Satisfaction Questionnaire (PSQ). Participants will be asked to complete the assessment while referring to their image in the mirror and current post-treatment photos compared to baseline photos. Specifically, participants will be asked to "Please choose the option that better represents the change in your hair THICKNESS in the area treated?" using a scale ranging from -3 (Greatly decreased) to 3 (Greatly increased). A score of zero represents no change. Scores will be summarized by study arm using descriptive statistics.
Outcome Time Frame
Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, and Month 15
Outcome Measure
Subject Satisfaction - Hair Thickness
Outcome Description
Subject satisfaction with hair shedding/loss will be assessed using a Patient Satisfaction Questionnaire (PSQ). Participants will be asked to complete the assessment while referring to their image in the mirror and current post-treatment photos compared to baseline photos. Specifically, participants will be asked to "Please choose the option that better represents the change in your hair SHEDDING/LOSS in the area treated?" using a scale ranging from -3 (Greatly decreased) to 3 (Greatly increased). A score of zero represents no change. Scores will be summarized by study arm using descriptive statistics.
Outcome Time Frame
Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, and Month 15
Outcome Measure
Subject Satisfaction - Hair Shedding/Loss
Outcome Description
Subject satisfaction with hair darkness will be assessed using a Patient Satisfaction Questionnaire (PSQ). Participants will be asked to complete the assessment while referring to their image in the mirror and current post-treatment photos compared to baseline photos. Specifically, participants will be asked to "Please choose the option that better represents the change in your hair DARKNESS in the area treated?" using a scale ranging from -3 (Greatly decreased) to 3 (Greatly increased). A score of zero represents no change. Scores will be summarized by study arm using descriptive statistics.
Outcome Time Frame
Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, and Month 15
Outcome Measure
Subject Satisfaction - Hair Darkness
Outcome Description
Subject satisfaction with treatment will be assessed using a Patient Satisfaction Questionnaire (PSQ). Participants will be asked to complete the assessment while referring to their image in the mirror and current post-treatment photos compared to baseline photos. Specifically, participants will be asked "How would you characterize your satisfaction with the treatment?" based on the following ordinal scale: Very Satisfied; Satisfied; Slightly Satisfied; Neither satisfied nor dissatisfied; or Dissatisfied. Results will be summarized by study arm.
Outcome Time Frame
Month 1, Month 2, Month 3, Month 6, Month 9, Month 12, and Month 15
Outcome Measure
Subject Satisfaction - Satisfaction with Treatment
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Actual
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
99
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Kseniya Kobets
Investigator Email
kkobets@montefiore.org
Investigator Phone
718-920-8352
Investigator Department
Medicine
Investigator Division
Dermatology
Investigator Sponsor Organization
Montefiore
Study Department
Medicine
Study Division
Dermatology
Categories Mesh Debug
Skin/Dermatology --- ALOPECIA
MeSH Terms
ALOPECIA
HYPOTRICHOSIS
HAIR DISEASES
SKIN DISEASES
SKIN AND CONNECTIVE TISSUE DISEASES
PATHOLOGICAL CONDITIONS, ANATOMICAL
PATHOLOGICAL CONDITIONS, SIGNS AND SYMPTOMS